🎉 M&A multiples are live!
Check it out!

Cellectis Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cellectis and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Cellectis Overview

About Cellectis

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.


Founded

2000

HQ

France
Employees

222

Website

cellectis.com

Financials

LTM Revenue $49.1M

LTM EBITDA -$64.7M

EV

$35.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Cellectis Financials

Cellectis has a last 12-month revenue of $49.1M and a last 12-month EBITDA of -$64.7M.

In the most recent fiscal year, Cellectis achieved revenue of $44.6M and an EBITDA of -$10.2M.

Cellectis expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Cellectis valuation multiples based on analyst estimates

Cellectis P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.8M $44.6M XXX XXX XXX
Gross Profit $18.7M $19K XXX XXX XXX
Gross Margin 2305% 0% XXX XXX XXX
EBITDA -$99.5M -$10.2M XXX XXX XXX
EBITDA Margin -12270% -23% XXX XXX XXX
Net Profit -$114M -$109M XXX XXX XXX
Net Margin -14058% -243% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Cellectis Stock Performance

As of April 15, 2025, Cellectis's stock price is EUR 2 (or $2).

Cellectis has current market cap of EUR 182M (or $195M), and EV of EUR 33.0M (or $35.5M).

See Cellectis trading valuation data

Cellectis Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$35.5M $195M XXX XXX XXX XXX $-0.41

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Cellectis Valuation Multiples

As of April 15, 2025, Cellectis has market cap of $195M and EV of $35.5M.

Cellectis's trades at 0.7x LTM EV/Revenue multiple, and -0.5x LTM EBITDA.

Analysts estimate Cellectis's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Cellectis and 10K+ public comps

Cellectis Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $35.5M XXX XXX XXX
EV/Revenue 0.8x XXX XXX XXX
EV/EBITDA -3.5x XXX XXX XXX
P/E -4.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Cellectis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Cellectis Valuation Multiples

Cellectis's NTM/LTM revenue growth is 9%

Cellectis's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.5M for the same period.

Over next 12 months, Cellectis's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Cellectis's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Cellectis and other 10K+ public comps

Cellectis Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 5397% XXX XXX XXX XXX
EBITDA Margin -23% XXX XXX XXX XXX
EBITDA Growth -90% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -13% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 42% XXX XXX XXX XXX
R&D Expenses to Revenue 218% XXX XXX XXX XXX
Opex to Revenue 243% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Cellectis Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Cellectis M&A and Investment Activity

Cellectis acquired  XXX companies to date.

Last acquisition by Cellectis was  XXXXXXXX, XXXXX XXXXX XXXXXX . Cellectis acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Cellectis

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Cellectis

When was Cellectis founded? Cellectis was founded in 2000.
Where is Cellectis headquartered? Cellectis is headquartered in France.
How many employees does Cellectis have? As of today, Cellectis has 222 employees.
Who is the CEO of Cellectis? Cellectis's CEO is Dr. Andre Choulika, PhD.
Is Cellectis publicy listed? Yes, Cellectis is a public company listed on PAR.
What is the stock symbol of Cellectis? Cellectis trades under ALCLS ticker.
When did Cellectis go public? Cellectis went public in 2007.
Who are competitors of Cellectis? Similar companies to Cellectis include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Cellectis? Cellectis's current market cap is $195M
What is the current revenue of Cellectis? Cellectis's last 12-month revenue is $49.1M.
What is the current EBITDA of Cellectis? Cellectis's last 12-month EBITDA is -$64.7M.
What is the current EV/Revenue multiple of Cellectis? Current revenue multiple of Cellectis is 0.7x.
What is the current EV/EBITDA multiple of Cellectis? Current EBITDA multiple of Cellectis is -0.5x.
What is the current revenue growth of Cellectis? Cellectis revenue growth between 2023 and 2024 was 5397%.
Is Cellectis profitable? Yes, Cellectis is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.